Browse drugs

… (r/rMM). Two BCMA-targeted CAR T cell therapies, cilta-cel and ide-cel, have received FDA approval and have demonstrated deep initial …

…st BCMA-negative HMC3 cells. In contrast, our novel CAR T-cell, LTG3551, exhibited low tonic signaling, compelling anti-tumor activity,…